<DOC>
	<DOCNO>NCT01733004</DOCNO>
	<brief_summary>This study Phase 1 pharmacologic open-labeled dose-escalation trial use `` 3+3 '' design , evaluate MM-141 vary dose level frequency .</brief_summary>
	<brief_title>A Phase 1 Study MM-141 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Advanced malignant solid tumor curative therapy exists recur pgrogressed follow standard therapy Eighteen year age Able understand sign inform consent ( legal representative able ) Measurable disease accord RECIST v1.1 ECOG Performance Score 0 1 Adequate bone marrow , hepatic , renal cardiac function Willing abstain sexual intercourse use effective form contraception study 90 day follow last dose MM141 Active infection fever &gt; 38.5Â°C screen visit first schedule day dose Symptomatic CNS disease Received recent antitumor therapy Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Oncology</keyword>
	<keyword>Phase I</keyword>
	<keyword>ErbB3</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Abraxane</keyword>
</DOC>